They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest ...

1 Recommendations 1.2 and 1.5 of that guideline stated that initial therapy with radiation and chemotherapy may be deferred in select patients with IDH-mutant WHO CNS grade 2 oligodendroglioma and ...

This truncated BRAF is constitutively active. The reports of rare fusions in diffuse astrocytomas and other nonpilocytic lesions suggest that such molecular changes involving BRAF are very common ...

There are four main types of astrocytomas: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme, each with varying degrees of aggressiveness and ...